Matsumoto-Miyai K, Kagase A, Yamada E, Yoshizumi M, Murakami M, Ohba T, Kawatani M. Store-operated Ca 2ϩ entry suppresses distention-induced ATP release from the urothelium. Am J Physiol Renal Physiol 300: F716 -F720, 2011. First published December 15, 2010; doi:10.1152/ajprenal.00512.2010.-Epithelial cells in the urinary bladder (urothelium) trigger sensory signals in micturition by releasing ATP in response to distention of the bladder wall. Our previous study revealed the distinct roles of extracellular Ca 2ϩ and the Ca 2ϩ stores in the endoplasmic reticulum (ER) in urothelial ATP release. In the present study, we investigated the regulation of urothelial ATP release by Ca 2ϩ influx from the extracellular space and Ca 2ϩ release from the ER using a distention assay of the mouse bladder wall in a small Ussing chamber. Stimulation of Ca 2ϩ release from the ER in the mucosal side of the bladder induced significant ATP release without distention. Blockade of the inositol 1,4,5-triphosphate receptor reduced distention-induced ATP release, suggesting that Ca 2ϩ release from the ER is essential for the induction of urothelial ATP release. On the other hand, blockade of store-operated Ca 2ϩ entry (SOCE) from the extracellular space significantly enhanced distention-induced ATP release. Thus Ca 2ϩ release from the ER causes urothelial ATP release and depletion of Ca 2ϩ stores in the ER, which in turn causes the depletion-inducing SOCE to suppress the amount of urothelial ATP released. urinary bladder; Ca 2ϩ release from the endoplasmic reticulum; Ca 2ϩ influx; urine storage THE UROTHELIUM RELEASES ATP in response to distention of the bladder wall during the phase of storage (3, 5). ATP receptor P2X 3 is expressed at the afferent nerve terminals in close proximity to the urothelium and is crucial for control of urinary bladder volume reflex. P2X 3 -deficient mice show urinary bladder hyporeflexia, such as attenuated response of bladder afferents to distention (26), and a decrease in voiding frequency with an increase in bladder capacity (9). The pain response behavior was also reduced in P2X 3 -deficient mice (9). Thus urothelial ATP release could play a key role in both volumeand noxious stimulus-evoked reflex. Hyperreflexia by excessive urothelial ATP release might cause frequent urination or bladder pain in the case of interstitial cystitis or an overactive bladder. In fact, an excess of urothelial ATP release was observed in interstitial cystitis (4, 23, 24) . In a group of female overactive bladder patients, those with a high ratio of urinary ATP/creatinine showed a higher symptom score of urinary frequency than those with a low ratio (22). Therefore, elucidation of the molecular mechanisms underlying urothelial ATP release would contribute to drug development for the therapeutic alleviation of storage symptoms or bladder pain.
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Previous studies show that activation of either TRPV1 or TRPV4 channels, which induce Ca 2ϩ influx, or the stimulation of chemical mediator receptors, which induce Ca 2ϩ release from the endoplasmic reticulum (ER), triggers urothelial ATP release (4, 6, 12-14, 18, 27) . This suggests that an increase in cytosolic Ca 2ϩ is essential for the induction of ATP release. On the other hand, our previous study suggested a different regulatory role of Ca 2ϩ influx in urothelial ATP release, with an elevation of extracellular Ca 2ϩ resulting in decreased amounts of ATP release (17) , implying that some types of Ca 2ϩ influx from the extracellular space might suppress the ATP release. To date, the distinct functions of Ca 2ϩ on urothelial ATP release are still unknown. In the present study, we investigated the dual roles of Ca 2ϩ in distention-induced ATP release from the urothelium using a dissected, opened urinary bladder mounted in an Ussing chamber. We adopted the change in ATP amount in the mucosal side of the chamber as an index of urothelial ATP release, because previous studies showed that 1) stimuli evoke ATP release from muscle-removed urinary bladder strips but not from mucosa-removed strips (11); and 2) stretching the urothelium induces ATP release into both the mucosal and serosal sides in a similar way (15) . Among various types of Ca 2ϩ influx, store-operated Ca 2ϩ entry (SOCE), a Ca 2ϩ influx induced by depletion of Ca 2ϩ stores in the ER (19, 20, 25) , is known to play important, unique roles in nonexcitable cells (19, 20) . However, the function of SOCE in the urothelium remains to be understood. Here, we focused on SOCE as a candidate of suppressive function on urothelial ATP release and investigated the opposite role of SOCE on distention-induced urothelial ATP release compared with that of Ca 2ϩ release from the ER.
MATERIALS AND METHODS
Animals. Eight-to 12-wk-old C57BL/6 male mice were used in this study. The Animal Research Committee of Akita University approved the protocols for the experiments, and the guidelines of the American Physiological Society for animal research were followed.
ATP release assay using the Ussing chamber. A total of 97 male mice were used for the Ussing chamber assay. The urothelial ATP release assay was performed as described previously (17) . In brief, isolated urinary bladders were opened vertically from the urethra to the apex. The opened bladder was mounted to act as a diaphragm of 7 mm 2 between the two halves of a customized small Ussing chamber. The mucosal (urinary) side of the chamber had a volume of 700 l. Chambers were filled with Krebs solution (117 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2, 24.8 mM NaHCO3, 1.2 mM NaH2PO4, and 11.1 mM glucose) including 0 mM or 2.5 mM CaCl2 with 95% O2/5% CO2 bubbling. In the chemical stimulation assay, Ca 2ϩ ionophore A23187 (Sigma, St. Louis, MO) or caffeine monohydrate (Wako, Osaka, Japan) was administered to the mucosal side for 30 min. Fifty microliters of Krebs solution was sampled from the mucosal side before and after its administration. The ATP release was assessed by subtracting the ATP content before administration from that after administration.
We performed two types of distention stimulation assays. In the first assay, we applied hydrostatic pressure at 45 cmH 2O to the serosal (smooth muscle) side for 20 min twice. Fifty microliters of Krebs solution was sampled from the mucosal side before and after application of pressure. Heparin sodium salt (Sigma), 2-aminoethyl diphenylborinate (2-APB; Sigma), or 1-(5-chlornaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9; Sigma) was administered to the mucosal side 30 min before the second pressure application. The effects of drugs were assessed by the ratio of the second pressureinduced change in ATP content to the first. The experimental design of the distention stimulation assay is also illustrated in Figs. 2A and 3A. In the second assay, 5 cmH 2O of pressure was applied to the serosal side for 20 min once, which is thought to reflect the physiological range of pressure during urine storage. We sampled 50 l of Krebs solution in the mucosal side of chamber before and after application of pressure. Heparin or ML-9 was administrated 30 min before the pressure was applied. The ATP release was assessed by the subtraction of ATP content before administration from that after administration. The experimental design of the distention stimulation assay is also illustrated in Fig. 4A . The concentrations of drugs used in this study were determined according to previous studies about Ca 2ϩ functions (4, 7, 21) . Measurement of ATP concentration. The ATP content in 50 l of Krebs solution in the mucosal side of the chamber was assayed by means of the luciferin-luciferase method (Kikkoman, Tokyo, Japan) according to the manufacturer's protocol. Standard lines were constructed in each experiment using 3 ϫ 10 Ϫ7 , 3 ϫ 10 Ϫ8 , 3 ϫ 10 Ϫ9 , and 3 ϫ 10 Ϫ10 M ATP. Data analysis. Stimuli-elicited changes in ATP content were calculated by subtracting the value before the administration of chemicals or pressures. In the first distention stimulation assay, measuring the ratio of second pressure-induced ATP release to the first pressureinduced ATP release was performed to assess the effects of the inhibitors and to eliminate individual differences in bladder samples. Statistically significant differences were detected using the unpaired t-test. All data were expressed as means Ϯ SE.
RESULTS

Ca
2ϩ release from the ER drives ATP release from the urothelium. We stimulated Ca 2ϩ release from the ER by administering the Ca 2ϩ ionophore A23187 (10 M) or the ryanodine receptor agonist caffeine (10 mM) to the mucosal side of the Ussing chamber for 30 min. To exclude the effects of Ca 2ϩ influx, the bladder walls were incubated in Ca 2ϩ -free Krebs solution. Although the vehicle for A23187, DMSO (final concentration 0.1%) had a weak effect on increasing ATP (0.34 Ϯ 0.54 nM), the administration of A23187 significantly elevated ATP content (1.95 Ϯ 0.39 nM), much more than DMSO without hydrostatic pressure for distention (Fig. 1A) . Administration of Krebs solution slightly decreased ATP content (Ϫ0.42 Ϯ 0.41 nM) by the constitutive ATP degradation activity of ecto-ATPase, whereas caffeine, dissolved in Krebs solution, also induced a significant ATP release (1.00 Ϯ 0.27 nM) from the mucosal side of the bladder wall without distention (Fig. 1B) .
Blockade of Ca 2ϩ release from the ER inhibits distentioninduced urothelial ATP release. The involvement of Ca 2ϩ release from the ER in distention (45 cmH 2 O of pressure)-induced ATP release from the urothelium was investigated next. To exclude variance among bladder samples, we assessed the ratio of the second pressure-evoked ATP increase to the first pressure-evoked ATP increase in the same tissue. The inositol 1,4,5-triphosphate (IP 3 ) receptor blocker heparin (100 g/ml) or vehicle (H 2 O) was administered to the mucosal side for 30 min before the second pressure application (Fig. 2A) . The ratio of the second ATP to the first ATP by vehicle only was 0.58 Ϯ 0.14 in the presence of 2.5 mM CaCl 2 in Krebs solution (Fig. 2B) . Administration of heparin significantly reduced the second pressure-evoked ATP release by ϳ30% (0.18 Ϯ 0.05; Fig. 2B ). The reducing effect of heparin was also detected in the Ca 2ϩ -free Krebs solution. Although the ratio by addition of vehicle was lower in the absence of CaCl 2 (0.20 Ϯ 0.07), heparin significantly decreased the ratio (Ϫ0.19 Ϯ 0.16; Fig. 2B ). The minus value of the ratio means that the second pressure application decreased the ATP content in the mucosal side of chamber, which is due to smaller ATP release than constitutive ATP degradation.
Blockade of SOCE enhances distention-induced urothelial ATP release. We focused on SOCE in various types of Ca 2ϩ influx from the extracellular space, because SOCE plays important, unique roles in nonexcitable cells (19, 20) . To investigate the effect of SOCE on urothelial ATP release induced by 45 cmH 2 O of pressure, we administrated 2-APB (100 M), an inhibitor of SOCE (25) , into the mucosal side of the chamber between the first and second pressure applications (Fig. 3A) . The effect of 2-APB was evaluated by the ratio of the second pressure-evoked ATP increase to the first pressure-evoked ATP increase. Administration of ethanol (final 0.1%), the vehicle for 2-APB, showed a similar ratio of the second ATP release (0.66 Ϯ 0.04 in 2.5 mM CaCl 2 , 0.28 Ϯ 0.07 in 0 mM CaCl 2 ) to 0.1% H 2 O, which was used as a vehicle for heparin (see Fig. 3B ). 2-APB significantly enhanced ATP release by 2.47-fold when Krebs solution containing 2.5 mM CaCl 2 was used (1.62 Ϯ 0.37; Fig. 3B ). The enhancing effect was diminished in the absence of CaCl 2 in Krebs solution (0.24 Ϯ 0.03; Fig. 3B) , indicating that the effect of 2-APB was dependent on the presence of extracellular Ca 2ϩ . To confirm the involvement of SOCE in ATP release, we assessed the effect of a potent myosin light chain kinase inhibitor, ML-9, which is also reported to inhibit SOCE (25) . As shown in Fig. 4C , administration of ML-9 (100 M) facilitated ATP release in a similar way to 2-APB. Although DMSO (0.1%; the vehicle for ML-9) reduced the ratio of the second ATP (0.17 Ϯ 0.05 in 2.5 mM CaCl 2 , 0.19 Ϯ 0.05 in 0 mM CaCl 2 ) compared with 0.1% ethanol, a significant enhancing effect by ML-9 was detected (up to 2.74-fold) when it was in the presence of 2.5 mM CaCl 2 (0.47 Ϯ 0.12; Fig. 3C ). In Ca 2ϩ -free Krebs solution, ML-9 did not affect the ratio of the second ATP release (0.22 Ϯ 0.03; Fig. 3C ), which was the same for 2-APB. Ca 2ϩ release from the ER and SOCE also regulate urothelial ATP release induced by physiological range of pressure during urine storage. Previously, we found that ATP was released in proportion to 15-45 cmH 2 O of hydrostatic pressure (17) , implying that the physiological range of pressure-induced ATP release could be also regulated by Ca 2ϩ in a similar way, To confirm this possibility, we examined the effect of heparin and ML-9 on the ATP release induced by 5 cmH 2 O of pressure. 4B ). These data showed that the physiological range of pressure-induced ATP release was driven by Ca 2ϩ release from the ER, but was suppressed by SOCE.
DISCUSSION
In this study, we demonstrate the distinct role of Ca 2ϩ release from the ER and SOCE in urothelial ATP release using dissected urinary bladders of adult mice. Different types of ER Ca 2ϩ -releasing factors, a Ca 2ϩ ionophore (A23187) or a ryanodine receptor agonist (caffeine), increased ATP content to ϳ1.4 -1.6 nM in Ca 2ϩ -free Krebs solution without any other stimulation (Fig. 1 ). This suggests that Ca 2ϩ release from the ER is capable of inducing urothelial ATP release. The inducing effect of A23187 or caffeine was slightly less than that of 15 cmH 2 O of hydrostatic pressure (ϳ2 nM) in our previous study (17) . Conversely, blockade of Ca 2ϩ release from the ER by heparin significantly suppressed distention-induced ATP release in this study (Figs. 2B and 4B) . A similar effect of heparin has also been reported using primary cultures of feline urothelial cells (4) , supporting the notion that the effect of heparin is due to its action on urothelial cells. Heparin reduced the hydrostatic pressure (45 cmH 2 O)-induced ATP release to ϳ30% (under conditions of 2.5 mM CaCl 2 in Fig. 2B ), meaning that most of the distention-induced ATP release is triggered by Ca 2ϩ release from the ER. The reminder of ATP release could be dependent on Ca 2ϩ influx through mechanosensory channels such as TRPV1 or TRPV4, because both TRPV1-and TRPV4-deficient mice show impairment of stretch-evoked increases in intracellular Ca 2ϩ and ATP release from the urothelium (6, 12) . In agreement, the second pressure for distention evoked almost no increase in ATP under conditions of 0 mM extracellular CaCl 2 with heparin (Fig. 2B) .
Previously, we found an additional role for extracellular Ca 2ϩ in the regulation of urothelial ATP release (17) . Physiological levels of extracellular Ca 2ϩ have an inhibitory effect on ATP release, which is distinct from the driving role of Ca 2ϩ release from the ER or from Ca 2ϩ influx through mechanosensory channels. Using dissected bladder tissues, the removal of extracellular Ca 2ϩ enhanced the distention-evoked ATP release. In primary culture of urothelial cells, an increase in extracellular Ca 2ϩ reduced the amount of chemically induced ATP release, indicating that extracellular Ca 2ϩ directly acts on urothelial cells, not through suburothelial or smooth muscle cells. As a distinct suppressive effect of extracellular Ca 2ϩ on urothelial ATP release, we focused on the SOCE, which is induced by the depletion of Ca 2ϩ stores in the ER (19, 20, 25) . The molecular components of store-operated Ca 2ϩ channels are supposed to be the TRPC and Orai family members. Of these members, the most evidence comes from studies showing that TRPC1, Orai1, or Orai2 can form store-operated Ca 2ϩ Fig. 2 . Blockade of Ca 2ϩ release from the ER inhibits distention-induced urothelial ATP release. A: schematic representation of the experimental procedure for the distention-induced ATP release assay. Hydrostatic pressure (45 cmH2O for 20 min) was applied twice to a same bladder wall. ATP content was measured at the time point indicated by the arrows. Heparin or its vehicle (H2O) was administrated 30 min before the second pressure application. B: the ratio of the second pressure-induced change in ATP content in the mucosal side of chamber to the first pressure-induced change. Heparin (100 g/ml) is able to significantly reduce the ratio of the second pressure-induced ATP release compared with the vehicle in Krebs solution containing 2.5 mM CaCl2 or Ca 2ϩ -free Krebs solution (P Ͻ 0.05 vs. vehicle by unpaired t-test). Error bars indicate SE; n ϭ 6 in vehicle (2.5 mM CaCl2), 7 in heparin (2.5 mM CaCl2), 7 in vehicle (0 mM CaCl2), and 7 in heparin (0 mM CaCl2). channels (2, 25) . In the present study, we found that the mucosal administration of different types of SOCE blockers, 2-APB or ML-9 (25), significantly enhanced distention-evoked urothelial ATP release (Fig. 3) . The involvement of SOCE in ATP release is also supported by the dependency of the effects of 2-APB or ML-9 on extracellular Ca 2ϩ (Fig. 3, B and C) . These data indicate that SOCE suppresses urothelial ATP release in contrast to Ca 2ϩ release from the ER, although they both result in an increase in intracellular Ca 2ϩ . Previous studies show that the SOCE has a discrete role from Ca 2ϩ influx either through mechanosensory or voltage/ligand-gated channels or from Ca 2ϩ release from the ER (19) . For example, the SOCE specifically, directly regulates the activity of enzymes such as adenylate cyclase and nitric oxide synthase (NOS), which are held at the plasma membrane (19, 20) . The activity of adenylate cyclase type VI is inhibited by SOCE, but not by other types of Ca 2ϩ influx or Ca 2ϩ release from the ER (8, 10) . SOCE evokes the generation of 10-fold more nitric Fig. 3 . Blockade of store-operated Ca 2ϩ entry (SOCE) enhances distentioninduced urothelial ATP release. A: schematic representation of the experimental procedure for the distention-induced ATP release assay. Hydrostatic pressure (45 cmH2O for 20 min) was applied twice to the same bladder wall. ATP content was measured at the time point indicated by the arrows. 2-Aminoethyl diphenylborinate (2-APB), 1-(5-chlornaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9), or vehicle (ethanol for 2-APB or DMSO for ML-9) was administrated 30 min before the second pressure application. B and C show the ratio of second pressure-induced change in ATP content in the mucosal side of the chamber to the first pressure-induced change. B: 2-APB (100 M) significantly enhances the ratio of the second pressure-induced ATP release compared with the vehicle when Krebs solution containing 2.5 mM CaCl2 (P Ͻ 0.05 vs. vehicle by unpaired t-test) was used. The enhancing effect is not detected in conditions of Ca 2ϩ -free Krebs solution (NS, not significant). Error bars indicate SE; n ϭ 5 in vehicle (2.5 mM CaCl2), 6 in 2-APB (2.5 mM CaCl2), 5 in vehicle (0 mM CaCl2), and 4 in 2-APB (0 mM CaCl2). C: ML-9 (100 M) also significantly enhances the ratio of the second pressure-induced ATP release compared with the vehicle when Krebs solution containing 2.5 mM CaCl2 (P Ͻ 0.05 vs. vehicle by unpaired t-test) was used, but does not alter the ratio in conditions of Ca 2ϩ -free Krebs solution. Error bars indicate SE; n ϭ 7 in all conditions. Fig. 4 . Ca 2ϩ release from ER and SOCE also regulate physiological pressureinduced urothelial ATP release. A: schematic representation of the experimental procedure for the distention-induced ATP release assay. Hydrostatic pressure (5 cm H2O for 20 min) was applied once. ATP content was measured at the time point indicated by the arrows. Heparin, ML-9, or vehicle (H2O for heparin or DMSO for ML-9) was administrated 30 min before the pressure application. B and C: changes in ATP content in the mucosal side of the chamber 20 min after administration. B: heparin (100 g/ml) diminished 5 cmH2O of pressure-induced increase in ATP content when Krebs solution containing 2.5 mM CaCl2 (P Ͻ 0.05 vs. vehicle by unpaired t-test) was used. Error bars indicate SE; n ϭ 4 in all conditions. C: ML-9 (100 M) significantly enhanced 5 cmH2O of pressure-induced increase in ATP content in the presence of 2.5 mM CaCl2 in Krebs (P Ͻ 0.05 vs. vehicle by unpaired t-test). Error bars indicate SE; n ϭ 4 in vehicle and 5 in ML-9.
oxide than ionomycin-induced Ca 2ϩ influx (16) . Such specific regulation might be achieved by proximity in the same microdomain; TRPC1, adenylate cyclase type VI, and endothelial NOS are localized to lipid rafts or caveolae (1, 28) . The distinct suppressive function of SOCE in urothelial ATP release might therefore be mediated by its regulation of these enzyme activities.
Although the level of pressure at 45 cmH 2 O is higher than the normal pressure range during urine storage, we have previously shown that urothelial ATP release was proportional to the pressure range of 15-45 cmH 2 O (17). In addition, the inhibitory effect of heparin and the enhancing effect of ML-9 were also demonstrated in ATP release induced by 5 cmH 2 O of pressure in this study (Fig. 4) . These data indicate that the same regulatory system by Ca 2ϩ works in urothelial ATP release by the physiological pressure during the filling stage. The common functions of Ca 2ϩ release from the ER and SOCE at a broad range of pressure imply that this mechanism might be involved in both micturition and nociception pathways.
In summary, we have shown the dual, opposite roles of Ca 2ϩ in the regulation of distention-induced urothelial ATP release. Ca 2ϩ release from the ER drives ATP release, whereas SOCE inhibits it. Since SOCE is preceded by Ca 2ϩ release from the ER, SOCE might suppress the amount of ATP release triggered by Ca 2ϩ release from the ER and adjust it to a physiologically adequate level.
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